文献速递胸部肿瘤

初治晚期ALK阳性非小细胞肺癌患者早期循环肿瘤DNA动态与洛拉替尼疗效

Early Circulating Tumor DNA Dynamics and Efficacy of Lorlatinib in Patients With Treatment-Naive, Advanced, ALK-Positive NSCLC.
PubMed 文献 · J Thorac Oncol · 2023-06-07

在III期CROWN研究(NCT03052608)中,评估初治晚期ALK阳性NSCLC患者早期ctDNA动态与洛拉替尼疗效的关联。第4周时两治疗组平均VAF均较基线下降;洛拉替尼组dVAF≤0与更长PFS相关(HR=0.50,95%CI:0.23-1.12),克唑替尼组未见类似关联(HR=1.00,95%CI:0.49-2.03)。洛拉替尼组分子缓解者PFS更长(HR=0.37,95%CI:0.16-0.85),克唑替尼组分子缓解者与未缓解者PFS相似(HR=1.48,95%CI:0.67-3.30)。

要点

  • 第4周时洛拉替尼和克唑替尼两组平均VAF均较基线下降。
  • 洛拉替尼组dVAF≤0与更长PFS相关(HR=0.50,95%CI:0.23-1.12)。
  • 克唑替尼组未见dVAF与PFS的类似关联(HR=1.00,95%CI:0.49-2.03)。

核心结论

  • 在初治晚期ALK阳性NSCLC患者中,早期ctDNA动态预测洛拉替尼的更好结局,但未预测克唑替尼的结局。
  • 这些结果提示ctDNA或可用于监测并可能预测洛拉替尼治疗的疗效。

研究设计与样本

  • 正在进行的III期CROWN研究(NCT03052608),纳入初治晚期ALK阳性NSCLC患者。
  • 使用平均变异等位基因频率(VAF)、纵向平均VAF变化(dVAF)及与基线比值计算分子缓解。
  • 将疗效评估(无进展生存期[PFS]和客观缓解率)与个体患者ctDNA配对并分析关联。

主要发现

  • 与基线相比,第4周时两个治疗组的平均VAF均下降。
  • 考虑所有检测到的体细胞变异,洛拉替尼组dVAF≤0与更长PFS相关,dVAF≤0对比>0的HR=0.50(95%CI:0.23-1.12)。
  • 克唑替尼组未观察到类似关联(HR=1.00,95%CI:0.49-2.03)。
  • 洛拉替尼组分子缓解者较未缓解者PFS更长(HR=0.37,95%CI:0.16-0.85)。
  • 克唑替尼组分子缓解者与未缓解者PFS相似(HR=1.48,95%CI:0.67-3.30)。

临床怎么用

  • 作者认为,ctDNA或可用于监测并可能预测洛拉替尼治疗的疗效。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Circulating tumor DNA (ctDNA) has been used as a biomarker for prognostication and response to treatment. Here, we evaluate ctDNA as a potential biomarker for response to lorlatinib, a third-generation ALK tyrosine kinase inhibitor in patients with treatment-naive, advanced, ALK-positive NSCLC in the ongoing phase 3 CROWN study (NCT03052608). METHODS: Molecular responses were calculated using mean variant allele frequency (VAF), longitudinal mean change in VAF (dVAF), and ratio to baseline. Efficacy assessments (progression-free survival [PFS] and objective response rate) were paired with individual patient ctDNA and analyzed for association. RESULTS: Compared with baseline, mean VAF at week 4 was decreased in both treatment arms. Considering all detected somatic variants, a reduction in dVAF (≤0) was associated with a longer PFS in the lorlatinib arm. The hazard ratio (HR) for a dVAF less than or equal to 0 versus more than 0 was 0.50 (95% confidence interval [CI]: 0.23-1.12) in the lorlatinib arm. A similar association was not observed for crizotinib (HR = 1.00, 95% CI: 0.49-2.03). Comparing molecular responders with nonresponders, patients treated with lorlatinib who had a molecular response had longer PFS (HR = 0.37, 95% CI: 0.16-0.85); patients treated with crizotinib who had a molecular response had similar PFS as those without a molecular response (HR = 1.48, 95% CI: 0.67-3.30). CONCLUSIONS: In patients with treatment-naive, advanced, ALK-positive NSCLC, early ctDNA dynamics predicted better outcome with lorlatinib but not with crizotinib. These results suggest that ctDNA may be used to monitor and potentially predict efficacy of lorlatinib treatment.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Soo RA, Martini JF, van der Wekken AJ, et al. Early Circulating Tumor DNA Dynamics and Efficacy of Lorlatinib in Patients With Treatment-Naive, Advanced, ALK-Positive NSCLC. J Thorac Oncol. 2023. PMID: 37295609. doi:10.1016/j.jtho.2023.05.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。